Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

GlobeNewswire October 25, 2022

Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

GlobeNewswire October 5, 2022

Medicenna Extends Period to Exercise Certain Warrants

GlobeNewswire September 30, 2022

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

GlobeNewswire September 28, 2022

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

GlobeNewswire September 22, 2022

Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewswire September 21, 2022

Medicenna (TSX:MDNA) announces clinical collaboration with Merck

Trevor Abes  September 13, 2022

Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

GlobeNewswire September 13, 2022

Medicenna to Present at Investor and Scientific Conferences in September

GlobeNewswire September 8, 2022

Medicenna (TSX:MDNA) reports fiscal Q1 2023 financial results

Jonathon Brown August 15, 2022

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire August 15, 2022

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

GlobeNewswire August 11, 2022

Medicenna (TSX:MDNA) prices US$20 million public offering

Trevor Abes  August 9, 2022

Medicenna Announces Pricing of US$20 Million Public Offering of Units

GlobeNewswire August 9, 2022

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

GlobeNewswire August 8, 2022

Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022

GlobeNewswire August 5, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11's Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

GlobeNewswire July 27, 2022

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

GlobeNewswire June 22, 2022

Medicenna (TSX:MDNA) strengthens IP protection for Superkine platform with U.S. patent

Azuka Onwuka June 9, 2022

Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

GlobeNewswire June 9, 2022